GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (XTER:5CV) » Definitions » Cash Payments

CureVac NV (XTER:5CV) Cash Payments


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.